The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
Has cognitive ability to provide informed consent
Aged 22 years or older
Hospitalized with hypoxemia/respiratory distress
Diagnosis of COPD
Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
Hemodynamic instability (systolic blood pressure <90mmHg or requirement for vasopressor or inotropic support)
Patient receiving end of life care
Nasal or facial conditions precluding use of nasal high flow